Browse by author
Lookup NU author(s): Dr Petros PerrosORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Copyright © 2025 Bednarczuk, Sugier, Attanasio, Nagy, Negro, Papini, Žarković, Akarsu, Alevizaki, Ayvaz, Nedeljković Beleslin, Berta, Bodor, Borissova, Boyanov, Buffet, Burlacu, Cohen, Ćirić, Díez, Dobnig, Fadeyev, Field, Fliers, Führer-Sakel, Frølich, Galofré, Hakala, Jiskra, Kopp, Krebs, Kršek, Kužma, Lazúrová, Leenhardt, Ludgate, Luchytskiy, McGowan, Melo, Metso, Moran, Morgunova, Niculescu, Perić, Planck, Poiana, Puga, Robenshtok, Rosselet, Ruchala, Riis, Shepelkevich, Tronko, Unuane, Vardarli, Visser, Vryonidou, Younes, Yurenya, Perros and Hegedüs.Background: Managing patients with fatigue is a clinical challenge. Because fatigue is often reported in hypothyroidism, thyroid hormone (TH) therapy may sometimes be incorrectly considered for biochemically euthyroid individuals. This study aimed to evaluate the prevalence and determinants of this practice in different European countries. Methods: We analyzed aggregate data from the THESIS (Treatment of Hypothyroidism in Europe by Specialists: an International Survey) online survey. We analyzed responses from 5,695 members of 28 national endocrine/thyroid societies’ specialists to the statement: “Thyroid hormones may be indicated in biochemically euthyroid patients with unexplained fatigue”. Results: Overall, 7.5% (426/5695) of respondents indicated that TH therapy might be considered for euthyroid patients with unexplained fatigue. The proportion of positive responses varied widely across different countries (between 1.1% in Switzerland and 29.3% in Serbia; p=2 ×10-16) and regions (between 4.7% in Western Europe and 8.7% in Western Asia or 8.8% in Eastern Europe; p=0.004). TH were more frequently prescribed for unexplained fatigue by male respondents (Odds Ratio, OR 1.45, 95% CI 1.18-1.78) and physicians practicing in private practice (OR 1.27, 95% CI 1.02-1.58), and less frequently by endocrinologists (OR 0.62, 95% CI 0.46-0.83). Conclusion: A small, yet not negligible percentage of European thyroid-focused physicians consider using TH for euthyroid patients with unexplained fatigue, with significant variations based on geographic, demographic, and practice-related factors. Using levothyroxine and/or liothyronine in such cases lacks evidence and may partially contribute to the concerning overuse of TH therapy.
Author(s): Bednarczuk T, Sugier A, Attanasio R, Nagy EV, Negro R, Papini E, Zarkovic M, Akarsu E, Alevizaki M, Ayvaz G, Nedeljkovic Beleslin B, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu M-C, Cohen CA, Ciric J, Diez JJ, Dobnig H, Fadeyev V, Field BCT, Fliers E, Fuhrer-Sakel D, Frolich JS, Galofre JC, Hakala T, Jiskra J, Kopp PA, Krebs M, Krsek M, Kuzma M, Lazurova I, Leenhardt L, Ludgate S, Luchytskiy V, McGowan A, Melo M, Metso S, Moran C, Morgunova T, Niculescu DA, Peric B, Planck T, Poiana C, Puga FM, Robenshtok E, Rosselet P, Ruchala M, Riis KR, Shepelkevich A, Tronko MD, Unuane D, Vardarli I, Visser WE, Vryonidou A, Younes YR, Yurenya E, Perros P, Hegedus L
Publication type: Article
Publication status: Published
Journal: Frontiers in Endocrinology
Year: 2025
Volume: 16
Online publication date: 05/11/2025
Acceptance date: 20/10/2025
Date deposited: 02/12/2025
ISSN (electronic): 1664-2392
Publisher: Frontiers Media SA
URL: https://doi.org/10.3389/fendo.2025.1713814
DOI: 10.3389/fendo.2025.1713814
Data Access Statement: The datasets presented in this article are not readily available because Data is the property of the THESIS sub-committee. Requests to access the datasets should be directed to TB, tomasz.bednarczuk@wum.edu.pl.
Altmetrics provided by Altmetric
